
Pre-made Vopratelimab benchmark antibody ( Whole mAb, anti-ICOS therapeutic antibody, Anti-AILIM/CD278/CVID1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-629
Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
An agonistic humanized monoclonal antibody that recognizes inducible T-cell co-stimulator (ICOS; CD278), with potential antineoplastic activity. Upon administration, vopratelimab targets and binds to ICOS expressed on certain T cells.
Order information
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
GMP-Bios-ab-629-1mg | 1mg | 3090 | ||
GMP-Bios-ab-629-10mg | 10mg | 21890 | ||
GMP-Bios-ab-629-100mg | 100mg | 148000 | ||
GMP-Bios-ab-629-xmg | >100mg | Inquiry | ||
Shipping Cost: | 760.00 | |||
Total: | ||||
Description
Products Name (INN Index) | Pre-Made Vopratelimab biosimilar, Whole mAb, Anti-ICOS Antibody: Anti-AILIM/CD278/CVID1 therapeutic antibody |
INN Name | Vopratelimab |
Target | ICOS |
Format | Whole mAb |
Derivation | Humanized |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2017 |
Year Recommended | 2018 |
Companies | Jounce Therapeutics |
Conditions Approved | na |
Conditions Active | Solid tumours;Urogenital cancer;Non-small cell lung cancer |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- 6th Floor, Buiding No.2, Kangxin Road 3377, Shanghai, China
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
